15% off your order at United Lab Peptides: Visit unitedlabpeptides.com ↗
Healing

BPC-157

BPC-157 is a synthetic pentadecapeptide based on a partial sequence of a human gastric juice protective protein that has shown pro-angiogenic, anti-inflammatory, and tissue-protective effects across a wide range of preclinical (mostly rodent) injury models, while human evidence remains limited to small pilot studies and case series.

Research status: Extensive animal data on gut lining, tendon, and ligament repair. A 2025 pilot study has now examined IV safety in humans, but controlled human efficacy trials still don't exist.

This page is a research-orientation summary, not a dosing guide. For anything beyond general background, read the primary literature or talk to a qualified clinician — specifics like amount, frequency, or administration aren't something we publish here.

Peptide profile

What it does & how it works

BPC-157's healing effects appear to depend substantially on activation and up-regulation of VEGFR2, supporting new blood vessel formation (angiogenesis) in injured tissue. Research also points to modulation of the nitric oxide (NO) system, effects on growth hormone receptor expression, and influence on the FAK-paxillin pathway involved in cell adhesion, spreading, and migration. Broad anti-inflammatory and cytoprotective actions on epithelial and endothelial cells are consistently reported across these preclinical studies.

Typical results seen in research

In animal models, BPC-157 has accelerated healing of tendon, ligament, muscle, bone, and gastrointestinal tissue injuries, improved outcomes in experimental models of inflammatory bowel disease, and shown neuroprotective and analgesic activity. Human evidence is limited to small pilot studies and case series (for example, in musculoskeletal pain and interstitial cystitis) that suggest possible benefit but are far from sufficient to confirm efficacy; BPC-157 has not been approved by the FDA or other major regulators for any medical indication.

How it’s commonly used

In published research, BPC-157 has most often been administered by subcutaneous or intraperitoneal injection in animal models, with a smaller number of small human studies using oral, subcutaneous, or intravenous administration. Topical/local application has also been explored in some gastrointestinal and skin-injury research models, typically within short, injury-specific research periods.

Selected references

Curated from published literature for research orientation. Not an exhaustive review, and not a substitute for reading primary sources.

BPC-157 in the news

See all peptide news →

Related in Healing

← Compare vendor pricing on the Deals page

15% off your order at United Lab Peptides: Visit unitedlabpeptides.com ↗